Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Amphastar reported third-quarter 2026 revenue of $207.6 million, up 8% year over year, and GAAP net income of $37.8 million versus $17.4 million; adjusted non-GAAP diluted EPS rose to $1.14 from $0.93. Growth in BAQSIMI, Primatene MIST, lidocaine and newer products was partly offset by lower epinephrine and glucagon sales, while gross margin declined to 48.0% from 51.4%, partly amid remediation costs at its IMS subsidiary. The board authorized a $50 million increase to the share repurchase program, primarily to offset equity-compensation dilution.

Analysis

The headline EPS comparison flatters the operating trend: the year-ago quarter carried a large litigation provision, while this quarter’s gross profit was nearly flat despite revenue growth and gross margin contracted 340 bps. The key debate is whether new-product mix and volume can outgrow price erosion and IMS-related costs—not the reported GAAP EPS rebound. BAQSIMI’s volume growth is being partly surrendered through gross-to-net pressure; glucagon faces explicit competitive pricing, while Primatene’s price-led growth may be less durable than unit-led growth. Lidocaine’s shortage-driven demand is vulnerable to competitor supply returning. Ipratropium and teriparatide offer mix support, but launch-quarter sales do not establish a durable run rate.

The most consequential risk is IMS remediation: slower releases constrain revenue while remediation and idle/inefficient capacity can burden margins. FDA progress is therefore a two-sided catalyst—successful remediation could unlock supply and normalize costs, but delays can compound both. The $50 million authorization is better viewed initially as dilution management than a fresh, dependable source of shareholder yield; actual pace and net share reduction remain unverified. The contrarian read is that investors may over-credit the positive adjusted-EPS headline while underweighting nine-month adjusted earnings softness and margin compression. Near term, the conference call’s IMS timeline, product-level outlook, and gross-margin commentary matter more than pipeline market-size claims, which are not revenue forecasts.

Key Decisions for Investors

• Keep AMPH neutral into the call rather than chase the earnings headline. Reassess only after management clarifies IMS remediation milestones, release cadence, and expected cost burden; these are the highest-value near-term checks.
• If AMPH rallies materially on the headline without a credible margin/IMS improvement path, consider a tactical short or trim against a healthcare exposure. Thesis is falsified by sequential gross-margin recovery alongside evidence that IMS releases are normalizing; avoid setting a price target without current valuation and price data.
• Track quarterly gross margin, BAQSIMI gross-to-net/volume mix, and glucagon pricing. Persistent margin decline or further price-led sales weakness would argue the new-product mix is not offsetting erosion; sustained margin stabilization would invalidate that concern.
• Treat lidocaine shortage-related sales as potentially temporary and verify competitor supply conditions before extrapolating its growth. Separately monitor repurchase execution and diluted share count: the authorization is not equivalent to net buybacks or durable EPS accretion.